文献速递药物不良反应与药物警戒

肌萎缩侧索硬化作为药物不良反应:FDA不良事件报告系统的比例失衡分析

Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System.
PubMed 文献 · Drug Saf · 2022-05-24

本研究基于FDA不良事件报告系统2004年1月至2020年6月的数据,采用报告比值比(ROR)及95%CI进行比例失衡分析,共保留1188例肌萎缩侧索硬化病例。乌司奴单抗和奥马珠单抗的信号一致且出乎意料,提示免疫调节可能参与ALS发病。

要点

  • TNF-α抑制剂、乌司奴单抗、奥马珠单抗及他汀类等31种药物显示一致的ALS比例失衡信号。
  • 乌司奴单抗和奥马珠单抗与ALS的信号一致且出乎意料,需警惕免疫调节药物的潜在风险。
  • 结果受潜在疾病、反向因果和生物学合理性影响,不能直接推断因果关系。

核心结论

  • 药物可能通过免疫调节(如TNF-α抑制剂、乌司奴单抗、奥马珠单抗)以及影响代谢和骨骼肌完整性(如他汀类和双膦酸盐)促发ALS。
  • 补体和NF-kB失调可能是ALS作为药物不良反应的转化机制研究方向。

研究设计与样本

  • 基于FDA不良事件报告系统2004年1月至2020年6月季度数据的比例失衡分析,数据去重后保留1188例ALS病例。
  • 计算报告比值比(ROR)及95%置信区间作为比例失衡指标,并通过更宽泛查询、限制可疑药物、排除ALS作为适应症的报告评估稳健性。

主要发现

  • 31种药物具有一致的ROR稳定性,包括TNF-α抑制剂和他汀类。
  • 乌司奴单抗和奥马珠单抗的信号在各分析中一致且出乎意料。

临床怎么用

  • 临床药师应关注TNF-α抑制剂、乌司奴单抗、奥马珠单抗及他汀类等药物使用者的神经系统症状监测。
  • 对具有自身免疫背景的患者使用免疫调节药物时,需平衡获益与潜在的ALS风险信号。

局限性

  • 比例失衡分析无法确立因果关系,需考虑生物学合理性、潜在疾病和反向因果。
  • 数据来源于自发报告系统,存在报告偏倚和混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Amyotrophic lateral sclerosis is a fatal progressive disease with a still unclear multi-factorial etiology. This study focused on the potential relationship between drug exposure and the development of amyotrophic lateral sclerosis by performing a detailed analysis of events reported in the FDA Adverse Event Reporting System database. METHODS: The FDA Adverse Event Reporting System quarterly data (January 2004-June 2020) were downloaded and deduplicated. The reporting odds ratios and their 95% confidence intervals were calculated as a disproportionality measure. The robustness of the disproportion was assessed accounting for major confounders (i.e., using a broader query, restricting to suspect drugs, and excluding reports with amyotrophic lateral sclerosis as an indication). Disproportionality signals were prioritized based on their consistency across analyses (reporting odds ratio stability). RESULTS: We retained 1188 amyotrophic lateral sclerosis cases. Sixty-two drugs showed significant disproportionality for amyotrophic lateral sclerosis onset in at least one analysis, and 31 had consistent reporting odds ratio stability, including tumor necrosis factor-alpha inhibitors and statins. Disproportionality signals from ustekinumab, an immunomodulator against interleukins 12-23 used in autoimmune diseases, and the anti-IgE omalizumab were consistent among analyses and unexpected. CONCLUSIONS: For each drug emerging as possibly associated with amyotrophic lateral sclerosis onset, biological plausibility, underlying disease, and reverse causality could be argued. Our findings strengthened the plausibility of a precipitating role of drugs primarily through immunomodulation (e.g., tumor necrosis factor-alpha, ustekinumab, and omalizumab), but also by impacting metabolism and the musculoskeletal integrity (e.g., statins and bisphosphonates). Complement and NF-kB dysregulation could represent interesting topics for planning translational mechanistic studies on amyotrophic lateral sclerosis as an adverse drug effect.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Gaimari A, Fusaroli M, Raschi E, et al. Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System. Drug Saf. 2022. PMID: 35610460. doi:10.1007/s40264-022-01184-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。